DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
Open Access
- 11 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7), e20528
- https://doi.org/10.1371/journal.pone.0020528
Abstract
Two DNA vaccines were constructed encoding the ectodomain (domains I, II and III) of the DENV2 envelope protein (pE1D2) or only its domain III (pE2D2), fused to the human tissue plasminogen activator signal peptide (t-PA). The expression and secretion of recombinant proteins was confirmed in vitro in BHK cells transfected with the two plasmids, detected by immunofluorescence or immunoprecipitation of metabolically labeled gene products, using polyclonal and monoclonal antibodies against DENV2. Besides, results reveal that the ectodomain of the E protein can be efficiently expressed in vivo, in a mammalian system, without the prM protein that is hypothesized to act as a chaperonin during dengue infection. Balb/c mice were immunized with the DNA vaccines and challenged with a lethal dose of DENV2. All pE1D2-vaccinated mice survived challenge, while 45% of animals immunized with the pE2D2 died after infection. Furthermore, only 10% of pE1D2-immunized mice presented some clinical signs of infection after challenge, whereas most of animals inoculated with the pE2D2 showed effects of the disease with high morbidity degrees. Levels of neutralizing antibodies were significantly higher in pE1D2-vaccinated mice than in pE2D2-immunized animals, also suggesting that the pE1D2 vaccine was more protective than the pE2D2.Keywords
This publication has 60 references indexed in Scilit:
- CD4+ T Cells Are Not Required for the Induction of Dengue Virus-Specific CD8+ T Cell or Antibody Responses but Contribute to Protection after VaccinationThe Journal of Immunology, 2010
- Cross-Reacting Antibodies Enhance Dengue Virus Infection in HumansScience, 2010
- The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1PLoS Pathogens, 2010
- Development of a recombinant tetravalent dengue virus vaccine: Immunogenicity and efficacy studies in mice and monkeysVaccine, 2010
- Dengue virus neutralization by human immune sera: Role of envelope protein domain III-reactive antibodyVirology, 2009
- Characterization of dengue virus entry into HepG2 cellsJournal of Biomedical Science, 2009
- A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus MacaquesJournal of Virology, 2007
- Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genesVirology Journal, 2007
- Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virusArchiv für die gesamte Virusforschung, 1996
- A comparative study with various anesthetics in mice (pentobarbitone, ketamine-xylazine, carfentanyl-etomidate)Zeitschrift für Die Gesamte Experimentelle Medizin, 1984